Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology Benefits Most From EMA-FDA Pediatrics 'Cluster' Informal Advice

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and EMA staffers talk monthly on topics related to pediatric uses, resulting in 15 non-binding joint commentaries.

You may also be interested in...

Parallel EMA-FDA Pediatric Advice On The Cards For Companies

The European Medicines Agency is working on plans to supplement its early advice pilot on pediatric development by providing joint advice with the US FDA and, in some cases, by arranging for a three-way dialogue with companies.

EMA Pilot For Early Advice On Pediatric Research Finally Gets Going

EMA has gotten applications from sponsors for early advice on developing medicines for pediatric indications, under one-year pilot project.

Priority Review Vouchers Keep Coming, But Expiration Deadline Looms

FDA's authority to issue vouchers with new treatments for rare pediatric diseases expires in March 2016 unless Congress intervenes to extend the program.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts